Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

A Bayesian Group Sequential Approach to Safety Signal Detection.

A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials

Evaluation of Statistical Methods for Safety Signal Detection: a Simulation Study

Detecting Adverse Drug Event Signals from a Clinical CaseBase.

Bayesian Safety Surveillance with Adaptive Bias Correction

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Information‐based group sequential design for post‐market safety monitoring of medical products using real world data

Continuous Post-Market Sequential Safety Surveillance with Minimum Events to Signal

A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded Data

Simultaneous Confidence Intervals for Signal Detection and Ascertaining Precision of Adverse Event Rates in Clinical Trials

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Bayesian Approach for Design and Analysis of Medical Device Trials in the Era of Modern Clinical Studies

Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study

Statistical Monitoring of Safety in Clinical Trials

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

Robust safety monitoring and signal detection using alternatives to the standard poisson distribution

Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source

Quantitative Safety Monitoring in Clinical Trials: Application of Multiple Statistical Methodologies for Infrequent Events

Bayesian spatial cluster signal learning with application to adverse event (AE)

Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events

Applying causal inference and Bayesian statistics to understanding vaccine safety signals — a simulation study